Document:

First Amendment to Amended and Restated Executive Employment Agreement

 Exhibit 10.2 
 FIRST AMENDMENT TO AMENDED AND RESTATED 
 EXECUTIVE EMPLOYMENT
AGREEMENT 
 This FIRST AMENDMENT TO THE AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT dated May 1, 2010 (the
“First Amendment”) is made as of January 25, 2012 between ARIAD Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and Maria E. Cantor (the “Employee”). 

WHEREAS, the Company and the Employee previously entered into an Amended and Restated Executive Employment Agreement dated May 1,
2010 (the “Agreement”), and the parties hereto desire further to amend certain provisions of the Agreement. 
 NOW,
THEREFORE, in consideration of the promises set forth herein and for other good and valuable consideration, the receipt of which is hereby acknowledged, the parties hereto agree further to amend the Agreement as follows: 

I. Severance – Section 6.2: 
 The entirety of Section 6.2 shall be replaced with the following: 
 “6.2
In the event of a consummation of a Change in Control of the Company, and if, upon such occurrence or within the period of one year following such occurrence, the Company terminates the Employee’s employment without Cause or the Employee
resigns for “Good Reason” (as defined herein), then, subject to compliance with Section 10 below, (i) all stock awards, stock options, restricted stock or restricted stock units granted to the Employee and past bonuses in the
form of deferred compensation granted to the Employee shall immediately vest and remain fully exercisable through their original term with all rights; (ii) the Company shall continue to pay the Employee his then-current base salary for
twenty-four (24) months; and (iii) if the Employee makes an effective COBRA election regarding group health insurance, then the Company shall continue to provide the Employee with coverage under the Company’s group health plan at the
Company’s expense for a period of 

 
eighteen months following Employee’s separation from the Company. Except as otherwise required under Section 14.2, salary continuation payments referenced in Section 6.2(ii) above
shall begin on the first regular pay date following Employee’s separation from service. Finally, the payments and benefits described in this Section 6.2 shall not be available if Employee’s employment terminates due to death or
disability during the one-year period following a Change of Control. 
 II. Except as modified by this First Amendment, the
Agreement remains in full force and effect. 
  

			
	ARIAD PHARMACEUTICALS, INC.,
		
	By:	 	 /s/ Harvey J. Berger, M.D.

		 	Harvey J. Berger, M.D.
		 	Chairman and Chief Executive Officer
	
	EMPLOYEE,
		
		 	 /s/ Maria E. Cantor

		 	Maria E. Cantor

 DATED: January 25, 2012 

  
 2First Amendment to Amended and Restated Executive Employment Agreement

 Exhibit 10.3 
 FIRST AMENDMENT TO AMENDED AND RESTATED 
 EXECUTIVE EMPLOYMENT
AGREEMENT 
 This FIRST AMENDMENT TO THE AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT dated May 1, 2010 (the
“First Amendment”) is made as of January 25, 2012 between ARIAD Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and Frank G. Haluska, M.D., Ph.D. (the “Employee”). 

WHEREAS, the Company and the Employee previously entered into an Amended and Restated Executive Employment Agreement dated May 1,
2010 (the “Agreement”), and the parties hereto desire further to amend certain provisions of the Agreement. 
 NOW,
THEREFORE, in consideration of the promises set forth herein and for other good and valuable consideration, the receipt of which is hereby acknowledged, the parties hereto agree further to amend the Agreement as follows: 

I. Severance – Section 6.2: 
 The entirety of Section 6.2 shall be replaced with the following: 
 “6.2
In the event of a consummation of a Change in Control of the Company, and if, upon such occurrence or within the period of one year following such occurrence, the Company terminates the Employee’s employment without Cause or the Employee
resigns for “Good Reason” (as defined herein), then, subject to compliance with Section 10 below, (i) all stock awards, stock options, restricted stock or restricted stock units granted to the Employee and past bonuses in the
form of deferred compensation granted to the Employee shall immediately vest and remain fully exercisable through their original term with all rights; (ii) the Company shall continue to pay the Employee his then-current base salary for
twenty-four (24) months; and (iii) if the Employee makes an effective COBRA election regarding group health insurance, then the Company shall continue to provide the Employee with coverage under the Company’s group health plan at the
Company’s expense for a period of 

 
eighteen months following Employee’s separation from the Company. Except as otherwise required under Section 14.2, salary continuation payments referenced in Section 6.2(ii) above
shall begin on the first regular pay date following Employee’s separation from service. Finally, the payments and benefits described in this Section 6.2 shall not be available if Employee’s employment terminates due to death or
disability during the one-year period following a Change of Control. 
 II. Definition of “Good Reason”:

 The definition of “Good Reason” in Section 15(g) of the Agreement shall be replaced, in its entirety, with the
following: 
 “(g) “Good Reason” means the occurrence of one or more of the following conditions arising without
the Employee’s voluntary consent: 
 (i) any requirement that the Employee relocate to a worksite that would
increase the Employee’s one-way commuting distance by more than twenty-five (25) miles, provided that the Employee gives notice to the Company within ninety (90) days of the relocation and the increase in commuting distance is not
cured within thirty (30) days of such notice; 
 (ii) the Company’s material breach of any provision of
this Agreement with the Employee, provided that the Employee gives notice to the Company within ninety (90) days of the initial occurrence of the breach and it is not cured within thirty (30) days of such notice; or 

(iii) the material diminution of Employee’s roles, responsibilities, scope of authority, or level in the overall
management structure or hierarchy of the Company and/or the entity resulting from a Change in Control, provided that the Employee gives notice to the Company within ninety (90) days of the initial occurrence of the material diminution, and it
is not cured within thirty (30) days of such notice. 
 For avoidance of doubt, a “material breach of any provision of this
Agreement” under clause (ii) above includes, without limitation, the Company’s failure to pay or provide salary, bonus or any other form of compensation referenced in Section 3 that is not corrected by the Company within thirty
(30) days after receiving notice from the Employee, provided such notice is provided by the Employee 

  
 2 

 
within ninety (90) days of the initial occurrence of the breach. This definition of “Good Reason” shall be interpreted consistent with the definition of an “involuntary
separation from service” under Section 1.409A-1 (n) of the Treasury Regulations.” 
 III. Except as modified
by this First Amendment, the Agreement remains in full force and effect. 
  

			
	ARIAD PHARMACEUTICALS, INC.,
		
	By:	 	 /s/ Harvey J. Berger

		 	Harvey J. Berger, M.D.
		 	Chairman and Chief Executive Officer
	
	EMPLOYEE,
	
	 /s/ Frank G. Haluska

	Frank G. Haluska, M.D., Ph.D.

 DATED: January 25, 2012 

  
 3Director Compensation Arrangements

 Exhibit 10.4 
 ARIAD Pharmaceuticals, Inc. 
 Director Compensation Arrangements

 Effective January 2, 2012 and until further modified by the Board of Directors of ARIAD Pharmaceuticals, Inc. (the
“Corporation”), the Corporation’s non-employee directors will receive the compensation set forth below. Non-employee directors do not receive any other compensation for service on the Board of Directors or its committees, other
than reimbursement of reasonable expenses. Directors who are also employees of the Corporation do not receive any additional compensation for their service on the Board of Directors. All equity awards are granted under the Corporation’s
2006 Long Term Incentive Plan, as amended. 
 Upon initial appointment to the Board of Directors, the director will receive a one-time grant of
40,000 stock options, which will vest over three years in equal amounts on first, second and third anniversaries of the date of grant. The options will have a term of ten years. The exercise price for such options will be the closing price of the
Corporation’s common stock as quoted on the NASDAQ Global Select Market on the date of grant. 
 Each year, the directors will receive
annual cash compensation of $50,000, paid in equal quarterly amounts on or about the last day of each calendar quarter. In lieu of cash, a director may elect to receive the equivalent value in restricted shares of the Corporation’s common stock
on January 31, subject to a lapsing repurchase right as described below. The number of shares will be determined based on the volume weighted average price (VWAP) of the Corporation’s common stock for the month of December of the prior
year. Such election will be made by January 15 of each calendar year. 
 Each year, the directors will receive an annual equity grant of
14,000 restricted shares of the Corporation’s common stock to be issued on January 31, subject to a lapsing repurchase right as described below. The number of restricted shares to be awarded will be evaluated annually to take into account
the underlying value of the shares. 
 The lapsing repurchase right will give the Corporation the right to repurchase the shares for a nominal
amount if the individual ceases to be a member of the Board of Directors or ceases to provide agreed upon services to the Corporation following their service as a director. The right will lapse as to 25% of the shares on
March 31, June 30, September 30 and December 31 of the year of the award. 
 The Board of Directors has adopted
stock ownership guidelines, to be phased in over five years, for the non-employee directors and the Corporation’s Chief Executive Officer. The guideline for the non-employee directors is ownership of the Corporation’s common stock with a
value of at least three times the annual cash compensation and the guideline for the Chief Executive Officer is ownership of the Corporation’s common stock with a value of at least six times his base salary.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}]]